The Blaze-1 clinical trial showed that COVID-19 patients who were treated with LY-CoV555 experienced a reduced rate of hospitalization by 72%. The rate of hospitalizations and emergency room visits was 1.7% for those treated with LY-CoV555 compared to 6% who were given placebos. Most hospitalizations occurred in those with underlying conditions.

In the randomized, double-blind, phase II study, mild-to-moderate recently diagnosed COVID-19 patients were given placebos or 700 mg, 2,800 mg, or 7,000 mg of LY-CoV555. Additionally, change from baseline in viral load at day 11 was met at the 2,800 mg dose but not at the others.

No patients were placed on ventilators or died, according to the company.

Sharing is caring: Why COVID-19 vaccine manufacturers must collaborate
Sharing knowledge between competitors will be key for establishing the manufacturing capacity needed to produce billions of COVID-19 vaccines in coming...

NIH launches clinical trial for COVID-19 antibody treatment
The National Institutes of Health (NIH) has started enrolling volunteers in a phase III randomized, controlled clinical trial to test multiple monoclonal...

NIH leads adaptive phase II clinical trial for COVID-19 mAb
The National Institutes of Health (NIH) is now studying an investigational monoclonal antibody (mAb), Ly-CoV555, as part of an adaptive phase II clinical...

Lilly begins phase III trial of COVID-19 antibody treatment
Eli Lilly has begun a phase III trial of its lead COVID-19 antibody treatment candidate, Ly-CoV555.